anti-PD-1 antibody · antibody
penpulimab
0 active trials across 2 of our biomarkers, targeting PD-1. Not approved for any biomarker on marked.bio yet.
Also known as AK105.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| HER2-low / ultralow (IHC 1+ or 2+/ISH-) | 0 | 1 | – |
| MSI-H / dMMR | 0 | 1 | – |
Trials
0 of 2 trials shown
-
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
Patients with HER2-low breast cancer confirmed by pathological examination, clinical stage II-III \[cT1N1,cT2 an…
HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer
-
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
Histopathologically confirmed MSI-H or dMMR advanced malignant solid tumors. 2.
MSI-H / dMMRMSI-H or dMMR Advanced Solid Tumors
No trials match these filters.